viewProactive Group

Investor Update: Faron Pharma's YODA study confirms Traumakine suspicions

Top stories from the Proactive Investors UK newsroom.

The much awaited feasibility study on Asiamet’s (LON:ARS) BKM project’s out this morning revealing an initial 9 year mine life producing up to 25,000 tonnes of copper cathode a year. The Post Tax NPV’s come in at $133.5 million.

Immotion Group PLC (LON:IMMO) has signed a three-year deal with Survios, a virtual reality (VR) studio backed by media firm MGM, for content to install in its new VR Arena.

Faron Pharmaceuticals Oy (LON:FARN) has released the final results of the YODA study into its interferon-beta drug Traumakine.  A phase III clinical trial – called “INTEREST” - on patients with a condition called acute respiratory distress syndrome didn’t yield the anticipated results, and the YODA study was instigated to find out why.

Frontier IP Group PLC’s (LON:FIPP) portfolio firm Exscientia has entered a drug discovery collaboration with Shanghai-based biotech GT Apeiron Therapeutics. As part of the partnership Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programme

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Kavango Resources' Mike Moles talks 'breakthrough' from new report on KSZ

Kavango Resources PLC's (LON:KAV) Mike Moles speaks to Proactive London's Andrew Scott following an update on its Kalahari Suture Zone prospect. An independent consultant’s report has confirmed two further characteristics of the geology of the project that are shared by the Norilsk deposits in...

28 minutes ago

2 min read